- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Wall Street Zen Upgrades Surrozen Stock to 'Hold'
Analysts cite improved outlook for the biotech company's Wnt-focused pipeline.
Mar. 28, 2026 at 5:33am
Got story updates? Submit your updates here. ›
Investment research firm Wall Street Zen has upgraded its rating on Surrozen (NASDAQ: SRZN) from 'sell' to 'hold', citing an improved outlook for the biotech company's pipeline of Wnt signaling pathway-targeting therapeutic antibodies.
Why it matters
Surrozen's SurroBody platform enables the development of bispecific antibodies that can modulate Wnt receptor activity, a critical pathway for cell proliferation, differentiation and homeostasis. The upgrade signals that Wall Street Zen sees potential in Surrozen's approach, which could have applications in tissue repair, regeneration and oncology.
The details
In a note to investors, Wall Street Zen analysts said they are now more optimistic about Surrozen's prospects after previously rating the stock a 'sell'. The upgrade comes as the company continues advancing its Wnt-focused pipeline, which includes several clinical-stage programs.
- Surrozen stock opened at $28.90 per share on Friday, March 28, 2026.
- The company reported Q4 2025 financial results on Monday, March 23, 2026.
The players
Wall Street Zen
An investment research firm that provides analysis and ratings on public companies.
Surrozen
A clinical-stage biopharmaceutical company focused on developing therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology.
What’s next
Investors will be closely watching for updates on Surrozen's clinical programs as the company continues to advance its Wnt-targeting therapeutic antibody candidates.
The takeaway
The upgrade from Wall Street Zen reflects growing confidence in Surrozen's innovative approach to modulating the Wnt signaling pathway, which could lead to new therapies in areas like tissue regeneration and oncology.
